MGT-1143 / Marigold Therapeutics - LARVOL DELTA

MGT-1143, a novel CDH17-targeting ADC for gastrointestinal cancers (AACR 2026) - "Collectively, the preclinical data support the continued development of MGT-1143 as a promising therapeutic candidate for the treatment of CDH17-positive gastrointestinal cancers. Ongoing IND-enabling studies will further define its safety and translational potential."

ADC • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17